CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer

CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer

Abstract Immune checkpoint blockade (ICB) improves outcomes in non-small cell lung cancer (NSCLC) though most patients progress. There are limited data regarding molecular predictors of progression. In particular, there is controversy regarding the role of CDKN2A loss-of-function (LOF) in ICB resist...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Stanley I. Gutiontov, William Tyler Turchan, Liam F. Spurr, Sherin J. Rouhani, Carolina Soto Chervin, George Steinhardt, Angela M. Lager, Pankhuri Wanjari, Renuka Malik, Philip P. Connell, Steven J. Chmura, Aditya Juloori, Philip C. Hoffman, Mark K. Ferguson, Jessica S. Donington, Jyoti D. Patel, Everett E. Vokes, Ralph R. Weichselbaum, Christine M. Bestvina, Jeremy P. Segal, Sean P. Pitroda
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/82195ffa5c7b45b097938796d4698839
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/82195ffa5c7b45b097938796d4698839

Ejemplares similares